Vaxiion Therapeutics

Vaxiion Therapeutics, founded in 2016 and based in San Diego, is advancing a novel, non-viral immunotherapy platform centered on engineered bacterial minicells. Its lead candidate, VAX014, is a first-in-class, tumor-targeted oncolytic immunotherapy currently in early-stage clinical trials for advanced solid tumors and non-muscle invasive bladder cancer. The company positions itself at the intersection of personalized medicine and immunotherapy, aiming to develop safer, more effective treatments for cancers resistant to standard therapies. With a focus on translating its proprietary science into patient outcomes, Vaxiion is a private, pre-revenue biotech building a pipeline of targeted immunotherapies.

Recombinant Bacterial Minicell (rBMC) platform for targeted delivery of immunotherapeutic payloads to tumors.

Vaxiion competes in the crowded cancer immunotherapy space against large pharma and biotech firms developing oncolytic viruses, cell therapies, and other immunomodulators. Its differentiation lies in its non-viral, engineered bacterial minicell approach, which must prove superior in targeting, safety, or efficacy to gain market share.